SCHEMBL6169403

SCHEMBL6169403

C[C@H]1[C@H](NC(=O)OC(C)(C)C)CN(Cc2ccccc2)CC1(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
NPFFR1 Q9GZQ6 2/20 0.43
NPFFR2 Q9Y5X5 2/20 0.43
DRD2 P14416 5/20 0.42
DRD4 P21917 4/20 0.42
DRD3 P35462 4/20 0.42
CTSK P43235 1/20 0.41
KCNA3 P22001 1/20 0.39
KDM1A O60341 1/20 0.39
MAOB P27338 1/20 0.39
MEN1 O00255 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA7 P43166 1/20 0.38
CA14 Q9ULX7 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
GRIN2B Q13224 1/20 0.38
GAA P10253 1/20 0.38
PDE4B Q07343 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6484125 1.00 KMT2A (0.49) KMT2AL3MBTL1NPFFR1NPFFR2DRD2
SCHEMBL6170475 0.88 KMT2A (0.48) KMT2AL3MBTL1NPFFR1NPFFR2DRD2
SCHEMBL6170470 0.88 KMT2A (0.48) KMT2AL3MBTL1NPFFR1NPFFR2DRD2
SCHEMBL6170476 0.88 KMT2A (0.48) KMT2AL3MBTL1NPFFR1NPFFR2DRD2
SCHEMBL7835003 0.84 KMT2A (0.55) KMT2AL3MBTL1NPFFR1NPFFR2DRD2
SCHEMBL19121559 0.84 KMT2A (0.55) KMT2AL3MBTL1NPFFR1NPFFR2DRD2
SCHEMBL3187533 0.84 KMT2A (0.55) KMT2AL3MBTL1NPFFR1NPFFR2DRD2
SCHEMBL7834998 0.84 KMT2A (0.55) KMT2AL3MBTL1NPFFR1NPFFR2DRD2
SCHEMBL3187519 0.84 KMT2A (0.55) KMT2AL3MBTL1NPFFR1NPFFR2DRD2
SCHEMBL1781856 0.84 KMT2A (0.55) KMT2AL3MBTL1NPFFR1NPFFR2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900224-B2 Antimicrobial quinolones, their compositions and uses THE PROCTER & GAMBLE COMPANY (US) 2005-05-31 US disclosed
EP-1532137-A2 ANTIMICROBIAL AZA-BICYCLIC DERIVATES, THEIR COMPOSITIONS AND USES THE PROCTER & GAMBLE COMPANY (US) 2005-05-25 EP disclosed
US-20040038975-A1 Antimicrobial quinolones, their compositions and uses THE PROCTER & GAMBLE COMPANY 2004-02-26 US disclosed
WO-2004014893-A2 ANTIMICROBIAL AZA-BICYCLIC DERIVATES, THEIR COMPOSITIONS AND USES THE PROCTER & GAMBLE COMPANY (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038975-A1 Antimicrobial quinolones, their compositions and uses QARS1, NQO2, Q6ZSR9 KMT2A 4196/4885L3MBTL1 3861/4885NPFFR1 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.